Equity Overview
Price & Market Data
Price: $2.32
Daily Change: -$0.17 / 7.33%
Range: $2.29 - $2.50
Market Cap: $65,511,652
Volume: 48,426
Performance Metrics
1 Week: -0.84%
1 Month: 18.69%
3 Months: 42.42%
6 Months: 7.31%
1 Year: 15.20%
YTD: 6.82%
Company Details
Employees: 21
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.